Description

MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F)[1].-4°C (Powder, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C73H113N13O19-Citation–References-[1]McCombs JR, et al. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015 Mar;17(2):339-51.-CASNumber–MolecularWeight-1476.75-Compound Purity-98.56-SMILES-CN([C@H](C(N[C@H](C(N([C@H]([C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@@H](CC2=CC=CC=C2)C(O)=O)=O)=O)OC)[C@H](CC)C)C)=O)C(C)C)=O)C(C)C)N(C)C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCNC(CCN4C(C=CC4=O)=O)=O)=O)=O)=O)C=C3)=O-Research_Area-Cancer-Solubility-DMSO : 230 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related